Skip to main content
. 2023 Aug 4;13:1214660. doi: 10.3389/fonc.2023.1214660

Figure 4.

Figure 4

(A) CT scan images of left chest wall disease progression at enrolment in the IMpassion131 trial. (B) CT scan images at enrolment in CLAG525B2101 trials. (C) Complete response after 6 months of treatment with olaparib; no contrast enhancement at PET-CT scan.